Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan

BACKGROUND: Although blinatumomab, a bispecific T cell engaging antibody, exhibits high clinical response rates in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (B-ALL) and B cell non-Hodgkin’s lymphoma (B-NHL), it still has some limitations because of its short half-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hematol Oncol
Main Authors: Zhang, Xiaolong, Yang, Yuanyuan, Zhang, Leisheng, Lu, Yang, Zhang, Qing, Fan, Dongmei, Zhang, Yizhi, Zhang, Yanjun, Ye, Zhou, Xiong, Dongsheng
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5322661/
https://ncbi.nlm.nih.gov/pubmed/28228105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0397-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados